

The optimal treatment options for your mitral regurgitation patients - a case-based discussion

T. Geisler, M.D.

University Hospital Tübingen, Germany



Potential conflicts of interest

Speaker's name: Tobias Geisler

I have the following potential conflicts of interest to report:

Boston Scientific: Research grants

Edwards Lifesciences: Research grants, honoraria


Medtronic: Honoraria





PASCAL Ace and PASCAL Implants

Implant dimensions



For Professional use. See instructions for use. CE Marked medical device.





PASCAL Implants

Paddle

- PASCAL implant paddles meet the contour of the larger Spacer
 - Paddles meet at the distal end and gradually recede proximally
- PASCAL Ace implant paddles closely follow the centerline
 - The Spacer shape allows Paddles to close nearly parallel












PASCAL Implants

Paddle

PASCAL Ace:

- Narrower Paddle width
- Designed to improve navigation through chordae
- Improved visualization
 - Increased confidence during leaflet capture
 - Clasp width relative to Paddle width











PASCAL Implant Selection for Mitral Regurgitation

Where is PASCAL preferred?	Where is PASCAL Ace preferred?	Where do we need consensus?
Restricted / shorter leaflet	Commissural jet	Calcification near the grasping zone
FMR	Dense chordae	Large flail gap
	Longer leaflet	Extensive prolapse
	DMR	MVA < 4cm ²
		Severe tethering
		Clefts







Philip Raake, M.D.

University Clinic Heidelberg, Germany



Potential conflicts of interest

Speaker's name: Philip Raake

I have the following potential conflicts of interest to report:

Speaker and/or consultant honoraria:

Edwards, Medtronic, Abbott, Biotronik, Astra-Zeneca, Novartis, Bayer, Vifor, Daiichi-Sankyo, CTI GmbH, Diaplan, Elisabeth-KH Essen, Conventus Congressmanagement Jena, BDI, CMI Medizinische Ausstellungs- und Werbegeslischaft Wien, Herzzentrum Leipzig, Leipzig Heart Institute GmbH, Kelcon, Deutsche Gesellschaft für Kardiologie.


Research Grant: Pfizer, Else-Kröner-Fresenius-Stiftung






Flail leaflet P1/P2 - baseline

Patient, 84y, f MR 3+ (Carpentier II) NYHA III, LV-EF 52% V-Wave 33mmHg, PAs 65mmHg






MI III° (Carpentier II, Flail leaflet P1/P2)

Pre-implantation





Patient, 84y, f MR 3+ (Carpentier II) NYHA III, LV-EF 52% V-Wave 33mmHg, PAs 65mmHg



Grasping attempt – 1st PASCAL Ace


3D View





Patient, 84y, f MR 3+ (Carpentier II) NYHA III, LV-EF 52% V-Wave 33mmHg, PAs 65mmHg






Grasping attempt PASCAL Ace, 3D View

X-Plane View






Patient, 84y, f MR 3+ (Carpentier II) NYHA III, LV-EF 52% V-Wave 33mmHg, PAs 65mmHg







Patient, 84y, f MR 3+ (Carpentier II) NYHA III, LV-EF 52% V-Wave 33mmHg, PAs 65mmHg









PCRonline.com



PASCAL Case Presentation Restricted leaflet

Sam Dawkins, M.D.

John Radcliffe Hospital,
Oxford, UK



Potential conflicts of interest

Within the past 12 months, Sam Dawkins has had a financial interest/arrangement or affiliation with the organisations listed below:

Affiliation/Financial Relationship Consulting fees/Honoraria

Company

Edwards Lifesciences, Abbott Vascular






Case presentation


- 65 year old man
 - Presented with breathlessness
 - Chest pain 3 weeks previously
 - Severe 3 vessel coronary artery disease
 - Severe mitral regurgitation with severe left ventricular impairment
 - Full thickness lateral infarction on cardiac MRI
 - Deterioration requiring intra-aortic balloon pump







Transthoracic echocardiogram











Expert opinions, advice and all other information expressed represent contributors' views and not necessarily those of Edward's Lifesciences.






Case presentation

- Heart Team discussion
 - Increased risk for surgery (cardiogenic shock, severe left ventricular impairment and acute renal failure)
 - For mitral edge-to-edge repair and then percutaneous revascularisation of the viable territories





Baseline Transoesophageal Echocardiogram








PASCAL Implant



































































Expert opinions, advice and all other information expressed represent contributors' views and not necessarily those of Edwards Lifesciences.






2nd PASCAL Implant













Expert opinions, advice and all other information expressed represent contributors' views and not necessarily those of Edward's Lifesciences.





















Adult Echo
X7-2t
14Hz
14Hz
12cm
0 100 100
89%
C 50
F Off
Gen
CF
48%
7104Hz
VF 639Hz
4 4MHz
PW
F 50%
WF 150Hz
SV4 0mm
2 \$MHz
4 .2cm
PAT T: 37 0C
TEE T: 39.5C

Expert opinions, advice and all other information expressed represent contributors' views and not necessarily those of Edwards Lifesciences.






Case presentation

- Intra-aortic balloon pump removed at end of procedure
- Inotropic support weaned over the next 3 days





Post-procedure transthoracic echocardiogram









PCRonline.com



PASCAL/PASCAL Ace switch

Dabit Arzamendi, M.D., PhD Hospital de la Santa Creu i Sant Pau Barcelona, Spain



Potential conflicts of interest

Speaker's name: Dabit Arzamendi

I have the following potential conflicts of interest to report:

- Abbott consulting fees/Honoraria.
- Edwards Lifesciences consulting fees/Honoraria.
- Boston Scientific consulting fees/Honoraria.
- Ivascular consulting fees/Honoraria.





Leaflet calcification in grasping zone - From PASCAL to PASCAL Ace

CLINICAL SUMMARY

- 84 yo male. PMH:
 - Ischemic cardiomyopathy (bypassx3 2009)
 - Afib
 - Moderate FMR
- Current medical history:
 - Dyspnea NYHA II-III
 - HF admission 2 months ago
 - Optimal medical therapy


- Heart-Team:
 - Prior surgery
 - IMF
 - Geriatrics: no frailty or sarcopenia
- Plan:
 - TEER with PASCAL Repair System





SCREENING TOE











TOE PROCEDURE: PASCAL Repair System













TOE PROCEDURE: PASCAL Repair System













DEVICE SWITCH










CLASPING WITH PASCAL Ace Implant











3D FINAL











High gradient - From PASCAL Ace to PASCAL

CLINICAL SUMMARY

- 61 yo female. PMH:
 - Heart transplant.
 - Severe FMR.
- Current medical history:
 - Dyspnea NYHA II-III.
 - HF admission 2 months ago.
 - Optimal medical therapy.


- Heart-Team:
 - FMR.
 - Prior heart transplant.
- Plan:
 - TEER with PASCAL Repair System





SCREENING TOE











TOE PROCEDURE: 3D POST PASCAL ACE IMPLANT










TOE PROCEDURE: MG POST PASCAL ACE IMPLANT










TOE PROCEDURE: LOW (VENTRICULAR) CLASPING OF PASCAL IMPLANT










TOE PROCEDURE: XPLANE POST PASCAL IMPLANTATION









TOE PROCEDURE: 3D POST PASCAL IMPLANTATION












TOE PROCEDURE: MG POST PASCAL IMPLANTATION









Thank You

Expert Opinions, advice and all other information expressed represent contributors' views and not necessarily those of Edwards Lifesciences.

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, PASCAL and PASCAL Ace are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2022 Edwards Lifesciences Corporation. All rights reserved. PP--EU-4298 v 1.0

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com







PCRonline.com